Search details
1.
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.
N Engl J Med
; 389(23): 2125-2139, 2023 Dec 07.
Article
in English
| MEDLINE | ID: mdl-37870968
2.
Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.
Cancer Sci
; 115(5): 1622-1633, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38429886
3.
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors.
Invest New Drugs
; 2024 Jun 04.
Article
in English
| MEDLINE | ID: mdl-38833067
4.
Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.
Cancer Sci
; 114(2): 574-585, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-35838190
5.
First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.
Cancer
; 129(15): 2348-2359, 2023 08 01.
Article
in English
| MEDLINE | ID: mdl-37080942
6.
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Br J Cancer
; 128(10): 1897-1905, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36871043
7.
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
N Engl J Med
; 383(13): 1207-1217, 2020 09 24.
Article
in English
| MEDLINE | ID: mdl-32955176
8.
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
Gastric Cancer
; 26(6): 1030-1039, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37665515
9.
[Japan or Global Development Trends in Cell Therapy].
Gan To Kagaku Ryoho
; 50(10): 1027-1031, 2023 Oct.
Article
in Japanese
| MEDLINE | ID: mdl-38035828
10.
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.
Lancet Oncol
; 23(1): 115-124, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34919824
11.
A phase 1 trial of xentuzumab, an IGF-neutralizing antibody, in Japanese patients with advanced solid tumors.
Cancer Sci
; 113(3): 1010-1017, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-34870878
12.
Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study.
Cancer Sci
; 113(8): 2788-2797, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35633184
13.
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.
Future Oncol
; 18(24): 2639-2649, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35815644
14.
Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors.
Int J Clin Oncol
; 27(9): 1413-1420, 2022 Sep.
Article
in English
| MEDLINE | ID: mdl-35713753
15.
Guidelines for clinical evaluation of anti-cancer drugs.
Cancer Sci
; 112(7): 2563-2577, 2021 Jul.
Article
in English
| MEDLINE | ID: mdl-33990993
16.
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
Invest New Drugs
; 39(6): 1568-1576, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34160752
17.
Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients.
Jpn J Clin Oncol
; 51(12): 1757-1760, 2021 Dec 01.
Article
in English
| MEDLINE | ID: mdl-34622931
18.
Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study.
Int J Clin Oncol
; 26(7): 1238-1247, 2021 Jul.
Article
in English
| MEDLINE | ID: mdl-33928486
19.
Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
Lancet Oncol
; 21(8): 1057-1065, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32589866
20.
Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer.
Gastric Cancer
; 23(5): 893-903, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32180056